Intarcia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies utilizing the Medici Drug Delivery System™ for the prevention and management of serious chronic diseases. The company focuses on diseases that are prevalent, poorly controlled, and growing at an epidemic rate, with a dual focus on preventive and therapeutic medicine.

Intarcia Therapeutics, Inc.

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Metric
Company Name	Intarcia Therapeutics, Inc.	Corcept Therapeutics Incorporated	Sutro Biopharma, Inc.
Symbol		CORT	STRO
MSH ID	COM:INTARCIA	COM:CORCEPT	COM:SUTROBIO
Market	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biopharmaceuticals	Biotechnology	Biotechnology
Country		US	US
Stage			Post-IPO Equity
Employee Count	251	352	300
Website	intarcia.com	corcept.com	sutrobio.com
LinkedIn
Founders

Metric
Market Cap	3.19B	294.46M
Enterprise Value
Monthly Web Traffic	53.48K	9.82K
Web Traffic Growth	3.98	0.04
Valuation
Raised Capital		75M

Metric
Revenue	482.38M	153.73M
Revenue (LTM)
Revenue (NTM)
Gross Profit	475.89M	146.91M
EBITDA	109.64M	-82.46M
Operating Income	107.28M	-89.28M
Net Income	106.14M	-106.79M
EPS	1.02	-1.78
Diluted EPS	0.94	-1.78
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.99	0.96
Operating Profit Margin	0.23	-0.58
EBITDA Margin	0.23	-0.54
Net Profit Margin	0.23	-0.69
Return on Equity	0.24	-0.71
Return on Assets	0.18	-0.23
Return on Capital Employed	0.22	-0.24

INTA

COM:INTARCIA

Intarcia Therapeutics, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	24.15	-1.56
P/B Ratio	4.78	2.42
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.13	4.33
EV Multiple	41.21	-1.22

Metric
Days Sales Outstanding	39.44	124.77
Days Payables Outstanding	1.00K
Days Inventory Outstanding	435.27	0.00
Operating Cycle	476.98	124.77
Cash Conversion Cycle	-212.43	-111.15
Asset Turnover	0.80	0.38

Metric
Operating Cash Flow	127.04M	-111.62M
Free Cash Flow	126.90M	-115.93M
Cash Flow to Debt	1.64K	-0.44
Operating Cash Flow/Sales	0.26	-0.44
Free Cash Flow Yield	0.07	-0.57

Metric
Cash & Equivalents	135.55M	69.27M
Accounts Receivable	-10.07M	-28.96M
Inventory	7.73M
Goodwill
Debt to Capitalization	0.01	0.62
Debt to Assets	0.00	0.09
Current Ratio	3.54	5.18
Quick Ratio	5.48	5.05

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.10	0.50
R&D to Revenue	0.37	3.49
SG&A to Revenue		1.24